Outcome of a cohort of severe cerebral venous thrombosis in intensive care
© Soyer et al. 2016
Received: 31 December 2015
Accepted: 28 March 2016
Published: 12 April 2016
Severity of cerebral venous thrombosis (CVT) may require the transfer to intensive care unit (ICU). This report described the context for CVT transfer to ICU, the strategy of care and the outcome after 1 year.
Monocentric cohort of 41 consecutive CVT admitted in a French ICU tertiary hospital (National Referent Center for CVT). Data collected are as follows: demographic data, clinical course, incidence of craniectomy and/or endovascular procedures and outcome in ICU, after 3 and 12 months.
47 years old (IQ 26–53), with 73.2 % were female, having a SAPS II 41 (32–45), GCS 7 (5–8), and at least one episode of mydriasis in 48.8 %. Thrombosis location was 80.5 % in lateral sinus and 53.7 % in superior sagittal sinus; intracranial hematoma was present in 78.0 %, signs of intracranial hypertension in 60.9 %, cerebral edema in 58.5 % and venous ischemia in 43.9 %. All patients received heparin therapy, and 9 cases had endovascular treatment (21.9 %); osmotherapy (53.7 %) and decompressive craniectomy (16 cases, 39 %) necessary to control intracranial hypertension. Ten patients/41 (24.4 %) died in ICU and 18/31 (58.1 %) were discharged from ICU with outcome 0–3 of mRS. After 12 months, 92 % of survivors (23/25) had a mRS between 0 and 3. The proportion of death was 31.7 % at 1 year.
The large proportion of acceptable outcome in survivors, which continue to functionally improve after 1 year, motivates the hospitalization in ICU for severe CVT. For similar CVT severity, craniectomy did not improve outcome in comparison with the absence of craniectomy.
KeywordsSevere cerebral venous thrombosis Intracranial hypertension Intracranial hematoma Decompressive craniectomy Endovascular therapies Neuro-resuscitation Multimodal monitoring
Cerebral venous thrombosis (CVT) is a difficult diagnosis of a rare brain vascular disease accounting for 0.5–1 % of all strokes [1, 2]. In the largest international multicenter cohort of CVT including 624 patients (ISCVT) with large spectrum of presentation, Ferro et al. showed a mortality rate of 4.3 % at the acute phase and 8.3 % at the last follow-up (16 months) . The authors mentioned 26 cases (4.1 %) with severe clinical presentations, but with elusive clinical information and care strategies and intensive care unit (ICU) hospitalization or not. Using the same database, the authors have reported  the main causes of death. Transtentorial herniation due to a unilateral focal mass effect or to diffuse edema and multiple parenchymal lesions were independent predictors of death. Coma , mental disturbance of deep CVT thrombosis, right intracerebral hemorrhage and posterior fossa lesion  were also associated with poor outcome. Recently, a study from multicenter registry had reported the outcome of 69 patients having decompressive craniectomy . If 31 patients came from the previously published registry, 34 were new cases or case reports. Although no information about incidence of ICU hospitalization, neuro-resuscitation and neuro-monitoring was mentioned, authors have reported unfavorable outcome (50 % of modified Rankin score (mRS) 4 or 5; or 42 % to die) when bilateral lesions were present compared to 11 % in unilateral lesions.
In our knowledge, there is no article on strategy of care and outcome of CVT patients requiring ICU admission. This study reports the profile of severe CVT transferred to ICU, the monitoring used, the strategy of care (supportive and instrumental interventions) with the observed complications and outcome in ICU and after 1 year.
Among the patients admitted to the neurological department of our institution (National Reference Center for CVT), some cases were transferred from 2002 to 2015 to our ICU for the following indications: severe alteration of consciousness or coma, status epilepticus, intracranial hypertension and/or requirement of mechanical ventilation. The diagnosis of CVT was usually established before ICU admission in all cases by CT (computerized tomography), venography, MRI (magnetic resonance imaging) or MRI combined with MR venography (MRV) and/or angiography.
The recorded clinical data were age, sex, medical history with special focus on malignancy and other known risk factors [3, 7, 8]. Clinical severity at ICU admission was evaluated by SAPS II, coma was graded with Glasgow Coma Scale (GCS), and presence of seizure, mydriasis and elevated intracranial pressure (ICP) (CT scan) were collected, as well as routine laboratory tests. The delay between the onset of neurological symptoms and ICU admission or between the diagnosis and ICU admission was also recorded.
Brain imaging techniques were as follows: CT scan, MRI and MRV interpreted by an independent radiologist (JPG). This evaluation had to mention the number and topography of the venous and sinus thrombosis, presence of hematoma, the associated brain damages related to venous congestion and presence of hydrocephalus.
The ICU strategy of care aimed to improve cerebral perfusion and oxygenation by classic means (central temperature <38 °C; arterial partial pressure in CO2 PaCO2 = 40; cerebral perfusion pressure >65 mmHg; and rigorous control of fluid balance). Monitoring consisted in invasive intra-arterial pressure (radial or femoral artery), end-tidal CO2 and middle cerebral artery transcranial Doppler velocities (Waki, Atys Medical, France; Ultrasound Echo-Doppler Vivid, General Electrics, USA). Treatment of CVT was based on heparin anticoagulation at therapeutic dose for all patients. The resistance to heparin was carefully checked by the delay to reach an adequate aPTT (activated partial thrombin time) (between two to three times of control). Interventional therapy such as invasive endovascular and neurosurgical lifesaving techniques was discussed collegially. Since venous circulation has a low intravascular pressure, moderate intracranial hypertension may impair venous flow, justifying the craniectomy. Endovascular treatment was decided when anticoagulation and control of cerebral perfusion and oxygenation were adequate but with occurrence of signs of uncontrolled intracranial hypertension. A CT scan was always performed before intervention to analyze the mass effect or the disappearance of cortical sulci and herniation.
Neurological complications were quoted and corresponded to a new episode of seizure, a new focal sign, new episode of hemorrhage or worsening of hematoma and post-interventional intracranial infection. The following extra-neurological complications were collected: remote thromboembolic episode, anticoagulation complications (extracranial bleeding and heparin-induced thrombocytopenia) and nosocomial infections.
The outcome study had consisted in evaluation of ICU death, a mRS at ICU discharge, repeated at 3 and 12 months and more when possible. Post-ICU outcome data were obtained from external consults made by a neurologist. As previously reported , the functional outcome was classified as follows: good recovery: mRS from 0 to 3; poor recovery: mRS 4 or 5; and death (mRS 6). The impact of craniectomy and/or endovascular treatment on death rate and functional outcome was also evaluated.
Clinical and biological quantitative variables were expressed as median and 25th–75th interquartiles. Intergroup comparisons were made by a Mann–Whitney test for quantitative variables and Chi-square test with Fischer correction for qualitative variables. A p < 0.05 was considered as statistically significant.
Admission in ICU
ICU admission main characteristics, supportive therapies, outcome for all patients and ICU survivors or dead
n = 41
n = 10
n = 31
Sex female (%)
Delay for diagnosis (days)
Delay diagnosis–ICU admission (days)
Seizure in ICU [n (%)]
Mydriasis [n (%)]
Hematoma [n (%)]
Heparin before admission [n (%)]
aPTT ratio > 2 within 48 h [n (%)]
Craniectomy (n (%))
Endovascular treatment [n (%)]
CSF shunt [n (%)]
IV norepinephrine [n (%)]
MAP min day 1 (mmHg)
MAP min day 2 (mmHg)
Mechanical ventilation [n (%)]
Fluid balance day 1 (mL)
−188 (−482 to +393)
−350 (−1224 to −145)
−188 (−440 to +429)
Fluid balance day 2 (mL)
247 (−756 to +809)
−50 (−679 to +878)
344 (−782 to +797)
Natremia day 1 (mM)
Platelet count day 1 (109/L)
Glycemia day 1 (mM)
mRS at discharge
mRS at 3 months (n = 23)
mRS at 12 months (n = 18)
mRS at last follow-up
Topography of brain lesions
Types of brain damage related to CVT in whole cohort, and ICU survivors or death
n = 41 (%)
n = 10 (%)
n = 31 (%)
Hematomas and hemorrhagic transformations
All patients were treated in ICU with unfractioned heparin targeting an aPTT ratio >2. This goal was obtained within the first 48 h in 30 patients (80.5 %). Cerebral perfusion was evaluated by transcranial Doppler in 32 patients (78.0 %) helping to optimize the strategy of care. In few cases (n = 8), intracranial pressure was monitored despite the risk of bleeding. When decided, the improvement in cerebral perfusion pressure required norepinephrine infusion in 26 patients (63.4 %), and 22 patients (53.7 %) had an osmotherapy to reduce cerebral edema.
Interventional treatment for thrombosis
Sixteen patients (39 %) had an early (48 h) craniectomy that was associated with evacuation of hematoma (n = 5) and cerebral spinal fluid (CSF) drainage (n = 4). Two patients had the 3 interventions. Nine patients underwent in situ endovascular treatment because of neurological deterioration or lack of improvement: 3 had a thrombectomy alone; 1 had a thrombolysis only; and 5 had a combination of the 2 treatments. In 6 patients, the venous circulation was restored with only 1 major parenchymal bleeding. The presence of severe intracranial hypertension is required to evacuate hematoma (n = 2), to perform a CSF drainage (n = 7) and/or to perform a craniectomy [uncontrolled pressure (n = 4)].
The total of dead patients after 1 year was 13/41 (31.7 %). Ten patients died in ICU (24.4 %) having similar delay between initial symptoms and diagnosis compared to survivors, with a more rapid deterioration to be transferred to ICU (p = 0.029) (Table 1). The clinical profile of dead patients compared to survivors was: predominance of female (p = 0.039), a worse initial GCS [4 (3–6); p = 0.0004], a more frequent mydriasis (100 vs. 32.3 %, p = 0.0001) with more frequent signs of intracranial hypertension on imaging techniques (p = 0.003), with a trend for more frequent use of norepinephrine (90 and 54.8 %, respectively) and more difficulty achieving therapeutic anticoagulation (50 vs. 80.6 %, respectively). Location of thrombosis, topography of parenchymal lesions or therapeutic strategy did not differ between the two groups (Tables 1, 2, and Additional file 2), with a trend for more frequent intracranial hematomas (100 and 70.9 %, respectively). Death rate was surprisingly the same when lesions were unilateral or bilateral (12.2 vs. 12. %). The 16 patients who underwent decompressive craniectomy did not differ from others CVT at ICU admission, but received norepinephrine more frequently (p = 0.018). They had frequent hematomas (93.8 and 68 %, respectively) and an anticoagulation more difficult to be adequate within 2 days (56.3 and 84 %, respectively). These patients had a similar 1-year outcome compared to patients who were not treated by craniectomy, although the mRS at ICU discharge and after 3 months tended to be worse (Additional file 3). The 9 patients who underwent an endovascular treatment were similar to the others, but tended to have more mydriasis (77.8 vs. 40.6 %, p = 0.067) and received more frequently norepinephrine infusion (p = 0.015). Their mortality rate in ICU and the mRS at discharge did not differ from the other patients (Additional file 3).
Despite maximal treatment, among the 10 patients who died in ICU, 9 had neurological complications such as uncontrolled ICHT or brain herniation and 1 patient died from massive pulmonary embolism. Observed ICU complications were as follows: seizures (n = 18); deterioration of hemorrhagic lesions under heparin treatment (n = 8, 19.5 %); nosocomial infections (craniectomy wound infection or ventriculitis, n = 4); pneumonia (n = 18, 43.9 %); urinary tract infections (n = 5, 12.2 %); and complications related to heparin treatment (n = 5): heparin-induced thrombocytopenia (n = 1), gastric hemorrhage (n = 1), gynecologic bleeding (n = 1), mesenteric hematoma with hemorrhagic shock (n = 1) and inguinal hematoma (n = 1).
The study first reports a cohort of patients with severe CVT admitted and treated in ICU, which provides information on clinical profile, management and outcome. The mortality of our cohort is higher than the one reported on patients having craniectomy , for whom little is known on clinical situation. However, the survivors of our cohort of very severe patients had a functional outcome almost identical to the one published in the ISCVT cohort having only 4 % of severe presentation . Our patients had a mRS between 0 and 3 in 88.5 %, a proportion similar to the 89.5 % in ISCVT cohort, who were not all treated in ICU. This suggests an effectiveness of both ICU care with tight monitoring associated with multi-disciplinary strategy discussion.
Characteristics and outcome
Apart from the severity, our cohort appeared similar for clinical characteristics to previous publications grouping all types of CVT. The patients were predominantly female, young, with multi-site thrombosis (thrombosis of superior sagittal sinus in 53.7 and 80.5 % in lateral sinuses) and classic risk factors for CVT, but with different proportions compared to previous reports . In the ISCVT cohort, 31 % had a lesion dominated by hematoma, which was 78.0 % in our cohort, an incidence that may explain the severity justifying ICU hospitalization. Few patients in ISCVT study had criteria for ICU admission (1.1 % of mechanical ventilation, 1.4 % surgery and 1.6 % shunts), proportions that largely differed from our cohort. Among the 32 patients having hematoma in our cohort, 10 patients died (31.3 %) during ICU stay. All patients deceased in ICU had an intracranial hematoma associated with lateral sinus thrombosis, previously reported to be a risk of death [4, 9]. Importantly, the unilateral or bilateral lesions had non-difference in mortality (12.2 % for both), a very different results when compared to the study on multiple registry . Although being more severe in our cohort, the survivors had similar rate of good outcome around 90 % after at least 1 year of evolution than those reported by others [3, 10–12].
Despite a worse functional outcome at ICU discharge, survivors had a positive evolution along the survey period: at the 1 year, only two patients over 26 (7.8 %) had a mRS at 4–5 and 4/26 (15.4 %) had a mRS 0. From 3 months till 1 year, functional outcome continued to improve as reported previously (Fig. 2) even for patients treated with invasive procedures such as craniectomy. Recently, the outcome and intracranial lesions of 69 patients with 45 treated by craniectomy were reported by Ferro et al. , with no information on ICU admission and strategy of care. The authors showed a good mRS 0–3 for 79 % with 16 % of them dying. The cohort of 44 craniectomy reported by Aaron et al.  had 59.3 % of mRS 0–3 at 3 months, a proportion that increased to 96.2 % after 1 year. Again, little information was given on ICU admission and treatment, which limits the comparison. Endovascular treatment was performed on 9 patients in our study for which 6 cases were considered successful. Our mortality rate for such patients was similar (33.3 %) to the one reported in 2008 using endovascular technique .
Strategy of care
In the absence of published ICU treatment in severe CVT, our results are difficult to compare. If the use of a multimodal neurological monitoring might logically help for therapies, this cannot be demonstrated. We believe it may help to reduce the delay for management decisions, especially for craniectomy and/or endovascular treatment. Since SvjO2 cannot be recommended and intracranial pressure monitoring exposes to intracranial bleeding, the use of transcranial Doppler velocity, blood pressure, careful control of arterial PaCO2 and neurological examination are key parameters to alarm on brain hypoperfusion. As an example, the trend for a decrease in mean cerebral artery diastolic velocity motivates to perform brain imaging and to discuss the benefit of invasive treatment, such as craniectomy and/or endovascular treatment as illustrated in the case report shown in Additional file 4. If anticoagulation by heparin is the hallmark treatment for CVT , even when intracranial hematoma is present, it might be difficult to manage. First, sometimes efficient anticoagulation can be obtained after a long delay (>48 h), during which thrombosis may worsen. A shift toward another therapy might be necessary, such as low molecular weight heparin and/or endovascular thrombolysis. A long delay to reach therapeutic anticoagulation may precipitate to death or might indicate decompressive craniectomy, especially in the presence of intracranial hematoma. Second, bleeding complications may occur as we observed for 8 patients having intracranial bleeding and 5 bleeding at different peripheral levels. However, after dose adjustment or shift to another anticoagulant, the anticoagulation was never stopped. If the use of LMW heparin has been suggested [16, 17], standard heparin appears safer for intensivist, since it can be neutralized if necessary.
Incidence of seizures was high (43.9 %) during ICU stay even when the patients were treated before arrival (recurrence 88.9 %, 16/18). This context may facilitate aspiration pneumonia or ICP elevation. Control of seizure episodes frequently required drug associations.
Craniectomy became in the last 5 years a credible treatment to reduce intracranial pressure and secondary ischemic lesions after severe CVT, helping the venous blood to circulate. Instead of arterial ischemia, the low level of venous pressure may push the decision to perform the craniectomy for relatively moderate ICP elevation. Cortical veins and collapsed veins may then recirculate, reducing venous congestion and improving venous blood flow in collaterals. In addition, it favors anticoagulant to reach the thrombosed venous side [8, 18]. The positive outcome of craniectomy in this and previous reports [6, 19–21] supports its interest to treat severe CVT. Consequently, the positioning of this procedure on the therapeutic decision tree will move from the rescue indication to a more regular treatment for deterioration of venous congestion despite anticoagulation .
The interest of endovascular therapies to improve survival rate and functional outcome remains speculative [14, 22, 23]. If the recanalization of thrombosed profound vessels sounds a reasonable goal to obtain a good outcome [24–26] as observed in our study, it is not clearly demonstrated yet. The ongoing randomized clinical trial (TO-ACT) comparing thrombolysis (with or without thrombosuction) + heparin therapy vs. heparin alone will perhaps answer this question . Decompressive craniectomy plus thrombolysis could be associated in the most severe cases, as we report in the case Additional file 4 [28, 29].
Limits of the study
First, our study is a one-center study with limited number cases, even the largest published in ICU. This disadvantage can be balanced by the homogenous strategy of care for a Reference Center. The ICU team is then well trained to care severe brain injury patients including CVT and to initiate meeting after warning from clinic or multimodal monitoring items to discuss potential additional interventional therapy. Second, it is a retrospective analysis, which cannot be easily prospective considering the low incidence of this disease. Third, the positioning of craniectomy and/or endovascular therapies cannot be finalized because of the small numbers of cases.
Severe CVT is rare among intensive care patients and differs largely from other severe brain injury admitted in ICU. An early and aggressive medical strategy is essential to prevent intracranial pressure elevation and improve venous drainage, which may require decompressive craniectomy or endovascular treatment. Despite a very severe initial clinical presentation, it is remarkable to observe an acceptable rate of death and frequent acceptable functional prognosis, which continues to improve after 1 year, as opposed to arterial brain ischemia.
activated partial thrombin time
cerebral spinal fluid
cerebral vein thrombosis
Glasgow Coma Scale
International Study on Cerebral Vein and Sinus Thrombosis 
intensive care unit
magnetic resonance imaging
modified Rankin score
magnetic resonance venography
- SAPS II:
Simplified Acute Physiology Score II
BS, MR, ACL and DP wrote the article. BS, MR, ACL and IC have collected the data. IC gave a large input about neurological aspects. BS and DP both finalized the final version of the manuscript. All authors read and approved the final manuscript.
Source of Funding: This work was supported in part by a University Grant from Ministry of Research (Plan Quadriennal 2009–2013).
IC has been and is still an investigator or an active member of committees for several trials testing CVT treatments such as TO-ACT trial. Other authors have no conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Bousser M-G, Ferro JM. Cerebral venous thrombosis: an update. Lancet Neurol. 2007;6:162–70.View ArticlePubMedGoogle Scholar
- Einhäupl K, Stam J, Bousser M-G, De Bruijn SFTM, Ferro JM, Martinelli I, Masuhr F. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol Off J Eur Fed Neurol Soc. 2010;17:1229–35.Google Scholar
- Ferro JM, Canhão P, Stam J, Bousser M-G, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke J Cereb Circ. 2004;35:664–70.View ArticleGoogle Scholar
- Canhão P, Ferro JM, Lindgren AG, Bousser M-G, Stam J, Barinagarrementeria F. Causes and predictors of death in cerebral venous thrombosis. Stroke J Cereb Circ. 2005;36:1720–5.View ArticleGoogle Scholar
- Ferro JM, Bacelar-Nicolau H, Rodrigues T, Bacelar-Nicolau L, Canhão P, Crassard I, Bousser M-G, Dutra AP, Massaro A, Mackowiack-Cordiolani M-A, Leys D, Fontes J, Stam J, Barinagarrementeria F. Risk score to predict the outcome of patients with cerebral vein and dural sinus thrombosis. Cerebrovasc Dis Basel Switz. 2009;28:39–44.View ArticleGoogle Scholar
- Ferro JM, Crassard I, Coutinho JM, Canhão P, Barinagarrementeria F, Cucchiara B, Derex L, Lichy C, Masjuan J, Massaro A, Matamala G, Poli S, Saadatnia M, Stolz E, Viana-Baptista M, Stam J, Bousser M-G. Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke J Cereb Circ. 2011;42:2825–31.View ArticleGoogle Scholar
- Saposnik G, Barinagarrementeria F, Brown RD Jr, Bushnell CD, Cucchiara B, Cushman M, deVeber G, Ferro JM, Tsai FY. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke J Cereb Circ. 2011;42:1158–92.View ArticleGoogle Scholar
- Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med. 2005;352:1791–8.View ArticlePubMedGoogle Scholar
- Girot M, Ferro JM, Canhão P, Stam J, Bousser M-G, Barinagarrementeria F, Leys D. Predictors of outcome in patients with cerebral venous thrombosis and intracerebral hemorrhage. Stroke J Cereb Circ. 2007;38:337–42.View ArticleGoogle Scholar
- Dentali F, Poli D, Scoditti U, Di Minno MND, Stefano VD, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, Vedovati MC, Ageno W, Falanga A, Lerede T, Bianchi M, Testa S, Witt D, McCool K, Bucherini E, Grifoni E, Coalizzo D, Benedetti R, Marietta M, Sessa M, Guaschino C, di Minno G, Tufano A, Barbar S, Malato A, Pini M, et al. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. J Thromb Haemost JTH. 2012;10:1297–302.View ArticlePubMedGoogle Scholar
- Narayan D, Kaul S, Ravishankar K, Suryaprabha T, Bandaru VCSS, Mridula KR, Jabeen SA, Alladi S, Meena AK, Borgohain R. Risk factors, clinical profile, and long-term outcome of 428 patients of cerebral sinus venous thrombosis: insights from Nizam’s Institute Venous Stroke Registry, Hyderabad (India). Neurol India. 2012;60:154–9.View ArticlePubMedGoogle Scholar
- Borhani Haghighi A, Edgell RC, Cruz-Flores S, Feen E, Piriyawat P, Vora N, Callison RC, Alshekhlee A. Mortality of cerebral venous-sinus thrombosis in a large national sample. Stroke J Cereb Circ. 2012;43:262–4.View ArticleGoogle Scholar
- Aaron S, Alexander M, Moorthy RK, Mani S, Mathew V, Patil AKB, Sivadasan A, Nair S, Joseph M, Thomas M, Prabhu K, Joseph BV, Rajshekhar V, Chacko AG. Decompressive craniectomy in cerebral venous thrombosis: a single centre experience. J Neurol Neurosurg Psychiatry. 2013;84:995–1000.View ArticlePubMedGoogle Scholar
- Stam J, Majoie CBLM, van Delden OM, van Lienden KP, Reekers JA. Endovascular thrombectomy and thrombolysis for severe cerebral sinus thrombosis: a prospective study. Stroke J Cereb Circ. 2008;39:1487–90.View ArticleGoogle Scholar
- Coutinho J, de Bruijn SF, Deveber G, Stam J. Anticoagulation for cerebral venous sinus thrombosis. Cochrane Database Syst Rev Online. 2011;(8):CD002005. doi:10.1002/14651858.CD002005.
- Coutinho JM, Ferro JM, Canhão P, Barinagarrementeria F, Bousser M-G, Stam J. Unfractionated or low-molecular weight heparin for the treatment of cerebral venous thrombosis. Stroke J Cereb Circ. 2010;41:2575–80.View ArticleGoogle Scholar
- Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol Off J Eur Fed Neurol Soc. 2012;19:1030–6.Google Scholar
- Weber J, Vida M, Greiner K. Sagittal sinus thrombosis with malignant brain oedema: pathophysiology of cortical veins after decompressive craniectomy. Acta Neurochir (Wien). 2013;155:651–3.View ArticleGoogle Scholar
- Théaudin M, Crassard I, Bresson D, Saliou G, Favrole P, Vahedi K, Denier C, Bousser M-G. Should decompressive surgery be performed in malignant cerebral venous thrombosis?: a series of 12 patients. Stroke J Cereb Circ. 2010;41:727–31.View ArticleGoogle Scholar
- Lath R, Kumar S, Reddy R, Boola GR, Ray A, Prabhakar S, Ranjan A. Decompressive surgery for severe cerebral venous sinus thrombosis. Neurol India. 2010;58:392–7.View ArticlePubMedGoogle Scholar
- Zuurbier SM, Coutinho JM, Majoie CBLM, Coert BA, van den Munckhof P, Stam J. Decompressive hemicraniectomy in severe cerebral venous thrombosis: a prospective case series. J Neurol. 2012;259:1099–105.View ArticlePubMedGoogle Scholar
- Ciccone A, Canhão P, Falcão F, Ferro JM, Sterzi R. Thrombolysis for cerebral vein and dural sinus thrombosis. Cochrane Database Syst Rev Online. 2004;(1):CD003693.
- Canhão P, Falcão F, Ferro JM. Thrombolytics for cerebral sinus thrombosis: a systematic review. Cerebrovasc Dis Basel Switz. 2003;15:159–66.View ArticleGoogle Scholar
- Dashti SR, Hu YC, Yao T, Fiorella D, Mitha AP, Albuquerque FC, McDougall CG. Mechanical thrombectomy as first-line treatment for venous sinus thrombosis: technical considerations and preliminary results using the AngioJet device. J Neurointerventional Surg. 2013;5:49–53.View ArticleGoogle Scholar
- Kumar S, Rajshekher G, Reddy CR, Venkateswarlu J, Prabhakar S. Intrasinus thrombolysis in cerebral venous sinus thrombosis: single-center experience in 19 patients. Neurol India. 2010;58:225–9.View ArticlePubMedGoogle Scholar
- Guo X, Guan S, Fan Y, Song L. Local thrombolysis for severe cerebral venous sinus thrombosis. AJNR Am J Neuroradiol. 2012;33:1187–90.View ArticlePubMedGoogle Scholar
- Coutinho JM, Ferro JM, Zuurbier SM, Mink MS, Canhão P, Crassard I, Majoie CB, Reekers JA, Houdart E, de Haan RJ, Bousser M-G, Stam J. Thrombolysis or anticoagulation for cerebral venous thrombosis: rationale and design of the TO-ACT trial. Int J Stroke Off J Int Stroke Soc. 2013;8:135–40.View ArticleGoogle Scholar
- Coutinho JM, Hama-Amin AD, Vleggeert-Lankamp C, Reekers JA, Stam J, Wermer MJH. Decompressive hemicraniectomy followed by endovascular thrombosuction in a patient with cerebral venous thrombosis. J Neurol. 2012;259:562–4.View ArticlePubMedGoogle Scholar
- Dohmen C, Galldiks N, Moeller-Hartmann W, Fink GR, Timmermann L. Sequential escalation of therapy in “malignant” cerebral venous and sinus thrombosis. Neurocrit Care. 2010;12:98–102.View ArticlePubMedGoogle Scholar